Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
ProMIS Neurosciences Inc. - Common Shares
(NQ:
PMN
)
0.9400
UNCHANGED
Streaming Delayed Price
Updated: 12:57 PM EST, Nov 29, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about ProMIS Neurosciences Inc. - Common Shares
< Previous
1
2
3
Next >
ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine
January 22, 2024
Lead vaccine candidate selected for advancement against synucleinopathies including Multiple System Atrophy, Parkinson’s disease and Dementia with Lewy bodies
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Why TransCode Therapeutics Shares Are Trading Lower By Over 24%? Here Are Other Stocks Moving In Friday's Mid-Day Session
January 19, 2024
Shares of TransCode Therapeutics, Inc. (NASDAQ: RNAZ) fell sharply during Friday’s session. TransCode Therapeutics priced a 5,942,623 share common stock offering at $1.22 per share. TransCode...
Via
Benzinga
ProMIS Neurosciences Issues Letter to Shareholders
January 08, 2024
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
ProMIS Neurosciences, Inc. Announces Leadership Transition
January 03, 2024
Appoints Neil Warma, Industry Leader and ProMIS Board Member, as Interim Chief Executive Officer
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
ProMIS Neurosciences Announces Publication on Novel Target for ALS
December 20, 2023
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
ProMIS Neurosciences Doses First Subjects in Phase 1a Clinical Trial of PMN310 to Treat Alzheimer’s Disease
November 20, 2023
Advances novel monoclonal antibody designed to be highly selective for toxic oligomers of amyloid-beta (Aβ) in first-in-human study
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
ProMIS Neurosciences Announces Third Quarter 2023 Financial Results and Recent Highlights
November 14, 2023
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
ProMIS Neurosciences Closes $20.4 Million Private Placement Financing
September 08, 2023
At-the-Market fundraise to support Company through several potentially value-creating milestones and beyond
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For October 3, 2023
October 03, 2023
Via
Benzinga
ProMIS Neurosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 06, 2023
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Crude Oil Falls; Dick's Sporting Goods Earnings Miss Views
August 22, 2023
U.S. stocks traded mostly lower toward the end of trading, with the Dow Jones falling over 100 points on Tuesday. The Dow traded down 0.39% to 34,330.87 while the NASDAQ rose 0.24% to 13,530.50. The...
Via
Benzinga
Topics
Earnings
Stocks
Exposures
Financial
Fossil Fuels
US Equities
Why ProMIS Neurosciences Shares Are Trading Higher By 33%; Here Are 20 Stocks Moving Premarket
August 22, 2023
Gainers Axcella Health Inc. (NASDAQ: AXLA) shares gained 65% to $0.2887 in pre-market trading after gaining 12% on Monday. The company recently posted a narrower-than-expected quarterly loss.
Via
Benzinga
Why Macy's Are Trading Lower By Around 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
August 22, 2023
Gainers Fulcrum Therapeutics, Inc. (NASDAQ: FULC) shares jumped 42.8% to $5.60 after the FDA lifted clinical hold on the company’s FTX-6058 for sickle cell disease.
Via
Benzinga
Exposures
Product Safety
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
August 22, 2023
We're starting off Tuesday with a breakdown of the biggest pre-market stock movers investors will want to keep an eye on!
Via
InvestorPlace
ProMIS Neurosciences Announces $20.4 Million Private Placement Financing
August 21, 2023
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
ProMIS Neurosciences Announces Second Quarter 2023 Financial Results and Recent Highlights
August 14, 2023
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Why Biophytis Shares Are Trading Higher By 54%; Here Are 20 Stocks Moving Premarket
July 18, 2023
Gainers Biophytis S.A. (NASDAQ: BPTS) shares surged 53.9% to $3.31 in pre-market trading after the company signed a partnership with SEQENS to produce Sarconeos (BIO101) active compound, the company's...
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
July 18, 2023
It's time to start off trading for Tuesday with a breakdown of the biggest pre-market stock movers worth watching this morning.
Via
InvestorPlace
Crude Oil Falls; GreenPower Motor Company Shares Spike Higher
July 17, 2023
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining 0.25% on Monday. The Dow traded up 0.25% to 34,596.04 while the NASDAQ rose 0.92% to 14,243.64. The S&P 500, also rose,...
Via
Benzinga
Why ProMIS Neurosciences Stock Surged Today
July 17, 2023
ProMIS Neurosciences Inc. (NASDAQ: PMN) shares skyrocketed Monday after the company presented preclinical data supporting the potential therapeutic advantage of its lead candidate for Alzheimer's...
Via
Benzinga
Nasdaq Gains 100 Points; Guaranty Bancshares Posts Upbeat Results
July 17, 2023
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 100 points on Monday. The Dow traded up 0.19% to 34,574.01 while the NASDAQ rose 0.71% to 14,214.50. The S&P...
Via
Benzinga
Why Acumen Pharmaceuticals Shares Are Trading Higher By Over 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
July 17, 2023
Gainers ProMIS Neurosciences, Inc. (NASDAQ: PMN) shares jumped 126.6% to $6.37. ProMIS showcased preclinical data at the Alzheimer's Association International Conference 2023 on computationally-derived...
Via
Benzinga
ProMIS Neurosciences (NASDAQ: PMN) Unveils Potential Therapeutic Advantage of PMN310 in Alzheimer’s Disease
July 17, 2023
Rationally Designed PMN310 Targets Toxic Amyloid-Beta Oligomers Selectively and Efficiently ProMIS Neurosciences, a pioneering biotech firm specializing in antibody therapeutics
Via
Spotlight Growth
US Stocks Edge Higher; NY Empire State Manufacturing Index Falls In July
July 17, 2023
U.S. stocks traded slightly higher this morning, with the Dow Jones moving higher by around 20 points on Monday. Following the market opening Monday, the Dow traded up 0.06% to 34,529.57 while the...
Via
Benzinga
ProMIS Showcases Preclinical Data at the Alzheimer’s Association International Conference 2023 on Computationally-Derived Antibody and Vaccine from Alzheimer’s Pipeline
July 17, 2023
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
ProMIS Announces Completion of Continuance
July 14, 2023
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Why Icahn Enterprises Shares Are Trading Higher By 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session
July 10, 2023
Gainers Mobilicom Limited (NASDAQ: MOB) shares jumped 81.3% to $2.7187 after the company announced it received a commercial scale purchase order from Teledyne-FLIR for the production of drones for the...
Via
Benzinga
ProMIS Neurosciences to Consolidate Trading on the Nasdaq Exchange
July 10, 2023
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
ProMIS Neurosciences Holds Annual Meeting of Shareholders All Resolutions Approved
June 30, 2023
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
CORRECTION: Updated URL to Access ProMIS Annual Meeting of Shareholders on June 29, 2023 at 9:30am Eastern Time
June 29, 2023
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.